Lyell Immunopharma
LYEL
117 hedge funds and large institutions have $177M invested in Lyell Immunopharma in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 20 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.11% less ownership
Funds ownership: 2.62% → 2.51% (-0.11%)
3% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 32
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2% less funds holding
Funds holding: 119 → 117 (-2)
9% less capital invested
Capital invested by funds: $194M → $177M (-$17.4M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.88M |
| 2 |
HF
HRT Financial
New York
|
+$836K |
| 3 |
Goldman Sachs
New York
|
+$710K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$484K |
| 5 |
BlackRock
New York
|
+$370K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SW
126
Simplicity Wealth
Summit,
New Jersey
| – | -$26.7K | -921 | Closed |
|
|
OAC
127
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$20.6K | -710 | Closed |
|
128
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$16.9K | -584 | Closed |
|
129
Russell Investments Group
London,
United Kingdom
| – | -$16.6K | -574 | Closed |
|
130
Simplex Trading
Chicago,
Illinois
| – | -$4.94K | -168 | Closed |
|
|
TSWM
131
Tyler-Stone Wealth Management
Beachwood,
Ohio
| – | -$1.23K | -43 | Closed |
|
132
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$732 | -25 | Closed |
|
133
Lazard Asset Management
New York
| – | -$500 | -17 | -65% |
|
|
RAM
134
Riggs Asset Management
Dallas,
Pennsylvania
| – | -$218 | -8 | Closed |
|
|
RIL
135
Rothschild Investment LLC
Chicago,
Illinois
| – | -$73 | -3 | Closed |
|
LYEL Hedge Fund Activity: Q3 2024 in Review
117 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2024, worth a combined $177M — down 9% from $194M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LYEL and 19 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 31 added.
The largest buyer was Morgan Stanley, adding an estimated $1.88M. The largest seller was Vanguard Group, cutting an estimated $4.89M.
- 117 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2024, down from 119 in Q2 2024.
- Funds reported $177M of Lyell Immunopharma stock for Q3 2024, down 9% quarter-over-quarter.
- 19 funds opened new Lyell Immunopharma positions in Q3 2024 and 20 closed out, a net change of -1 holder.
- The largest Lyell Immunopharma buyer in Q3 2024 was Morgan Stanley, an estimated $1.88M added.
- The largest Lyell Immunopharma seller in Q3 2024 was Vanguard Group, an estimated $4.89M sold.
Based on aggregated 13F filings for Q3 2024.